Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +2.87%81 EV-to-FCF is 28.63 as of Jul. 17, 2026, which is 12% below its 10-year median of 32.49. GuruFocus rates OSTO:MCAP with a GF Score™ of 81/100 and a GF Value™ of kr556.75 (Fairly Valued). Among 413 Medical Devices & Instruments companies, MedCap AB ranks worse than 57.63% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MedCap AB's Enterprise Value is kr7,864 Mil.
MedCap AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr275 Mil. Therefore, MedCap AB's EV-to-FCF for today is 28.63.
The historical rank and industry rank for MedCap AB's EV-to-FCF or its related term are showing as below:
OSTO:MCAP'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.69 Med: 32.49 Max: 102.57
Current: 27.59
During the past 13 years, the highest EV-to-FCF of MedCap AB was 102.57. The lowest was -22.69. And the median was 32.49.
OSTO:MCAP's EV-to-FCF is ranked worse than 57.63% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 23.72
vs OSTO:MCAP: 27.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MedCap AB's share price for today is kr519.50.
MedCap AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MedCap AB EV-to-FCF Related Terms
MedCap AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for MedCap AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MedCap AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MedCap AB's EV-to-FCF falls into.
MedCap AB's current Enterprise Value is kr7,864 Mil.
MedCap AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr275 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (OSTO:MCAP) has a EV-to-FCF of 28.63 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MedCap AB and its competitors. This is 12% below median its historical median of 32.49. According to the industry distribution chart, MedCap AB ranks #238 out of 413 companies in the Medical Devices & Instruments industry, placing it in the top 57.6%.
Is MedCap AB's EV-to-FCF too high?
MedCap AB's current EV-to-FCF of 28.63 is 12% below median its 10-year median of 32.49. The Medical Devices & Instruments industry median EV-to-FCF is 23.72. MedCap AB's value of 28.63 is 20.7% above this industry median. Based on the distribution chart, MedCap AB ranks #238 out of 413 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MedCap AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #238 out of 413 companies for EV-to-FCF. This places MedCap AB in the lower half of its industry. The industry median EV-to-FCF is 23.72. MedCap AB's value of 28.63 is 20.7% above this benchmark. While the company's 10-year median is 32.49 vs. the industry median of 23.72, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.72, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current EV-to-FCF of 28.63 is 20.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current EV-to-FCF is 28.63, which is 12% below median its own 10-year median of 32.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr556.75, compared to a current price of kr519.50 — trading 6.7% below its estimated fair value. The current EV-to-FCF is 28.63, which is 12% below median its 10-year median of 32.49 and 20.7% above the Medical Devices & Instruments industry median of 23.72. MedCap AB's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current EV-to-FCF is 28.63 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr519.50 is trading 6.7% below its estimated GF Value™ of kr556.75.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
EV-to-FCF: 28.63 (12% below median its 10-year median of 32.49)
GF Value™: kr556.75 vs. price of kr519.50 (6.7% below fair value)
Industry Position: 20.7% above the Medical Devices & Instruments median (#238 of 413)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
81GF Score
Get the complete analysis for OSTO:MCAP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
